Ligand Pharmaceuticals (LGND) Non-Current Assets (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Non-Current Assets data on file, last reported at $666.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 11.84% year-over-year to $666.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 billion (up 12.79% YoY), and the FY2025 full-year result was $728.4 million, up 19.36% from the prior year.
• Non-Current Assets fell to $666.7 million in Q1 2026, from $728.4 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $832.5 million in Q2 2022 to a low of $481.4 million in Q2 2023.
• A 5-year average of $628.5 million and a median of $596.1 million in 2025 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets sank 42.18% in 2023 and advanced 25.28% in 2024, its largest moves.
• Tracing LGND's Non-Current Assets over 5 years: stood at $499.1 million in 2022, then climbed by 10.16% to $549.8 million in 2023, then climbed by 10.99% to $610.2 million in 2024, then advanced by 19.36% to $728.4 million in 2025, then fell by 8.47% to $666.7 million in 2026.
• Business Quant data shows LGND's Non-Current Assets at $666.7 million in Q1 2026, $728.4 million in Q4 2025, and $722.9 million in Q3 2025.